SOCRATES trial of Brilinta / Brilique (ticagrelor) in stroke fails to meet endpoint- AstraZeneca

AstraZeneca announced top-line results of the SOCRATES trial, assessing the efficacy of Brilinta/Brilique (ticagrelor) 90mg tablets twice daily, when compared to aspirin 100mg once daily in patients with acute ischaemic stroke or transient ischaemic attack (TIA). The primary efficacy endpoint of time to first occurrence of any event from the composite of stroke (ischaemic or haemorrhagic), myocardial infarction (MI, also known as heart attack) and death was not met. Fewer events were observed on Brilinta/Brilique versus the comparator in the overall trial population but the trend did not reach statistical significance.

Based on preliminary analyses, safety data is consistent with the known safety profile of Brilinta/Brilique. The SOCRATES trial evaluated the efficacy and safety of 90-day treatment with Brilinta/Brilique versus aspirin for the prevention of major vascular events in patients older than 40 years of age with an acute ischaemic stroke (National Institutes of Health Stroke Scale 5 or less) or TIA (ABCD2 score of at least 4). Patients randomised into the trial needed to have symptom onset within 24 hours. In the second half of 2016, data are expected from the ongoing EUCLID trial in peripheral arterial disease (PAD). EUCLID is the fourth trial to read-out from the PARTHENON programme, assessing the potential of Brilinta/Brilique in additional high-risk patient population.

Comment: In the second half of 2016, data are expected from the ongoing EUCLID trial in peripheral arterial disease. EUCLID is the fourth trial to read-out from the PARTHENON programme, assessing the potential of Brilinta/Brilique in additional high-risk patient populations.